Cyprotex Highlights - November 2022
Cyprotex is delighted to announce the publication of a review article in Expert Opinion on Drug Metabolism and Toxicology. The article, authored by our Drug Transporter Sciences team, is entitled ‘Studying the Right Transporter at the Right Time: An In Vitro Strategy for Assessing Drug-Drug Interaction Risk During Drug Discovery and Development’.
Cyprotex recently presented the poster ‘Comparing Basic Static Models for Predicting Clinical CYP3A4 Induction Risk’ at the 2022 Joint DMDG/GMP/SPS conference in Amsterdam.
Read the poster here:
Join our experts Ralf Geiben Lynn, Chris Strock, Sravani Adusumalli, Anu Marahatta and Li Li at the NEDMDG in Cambridge, MA on the 5th December.
Click here to arrange a meeting with one of our team:
Read the latest news from parent company, Evotec:
- Evotec, CDP Venture Capital, and Angelini Ventures launch "Extend", a new BRIDGE partnership with leading Italian academic institutions
- Just - Evotec Biologics wins a 2022 CPhI Pharma Award for its flexible cGMP biomanufacturing plant J.POD®
- Evotec completes the acquisition of Central Glass Germany
Read more from Evotec, Cyprotex and Just - Evotec Biologics in the Science Pool blog:
.jpeg)
Telephone:
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683
Email:
info@evotec.eu